Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)

Trial Profile

Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)

Phase of Trial: Phase II

Latest Information Update: 13 Jul 2018

At a glance

  • Drugs Ixekizumab (Primary)
  • Indications Pityriasis rubra pilaris
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Apr 2018 Planned End Date changed from 31 Dec 2019 to 30 Nov 2019.
    • 30 Apr 2018 Status changed from not yet recruiting to recruiting.
    • 05 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top